Advancing Treatments for Rare Neurodevelopmental Disorders

Our mission is to improve the lives of patients and families by developing therapies with strong scientific foundations, meaningful evidence of clinical benefit, and clear unmet need

Our lead drug candidate is designed to provide a pediatric-friendly formulation of flunarizine for patients with Alternating Hemiplegia of Childhood, addressing the need for a consistent, age-appropriate treatment option in a disease where flunarizine has long been used clinically but remains unavailable in many regions of the world.